# Safety and Immunogenicity of MVA.HIVconsv in HIV-1 Seropositive Adults on HAART

> **NCT01024842** · PHASE1 · TERMINATED · sponsor: **University of Oxford** · enrollment: 19 (actual)

## Conditions studied

- HIV-1

## Interventions

- **BIOLOGICAL:** MVA.HIVconsv low dose
- **OTHER:** Placebo low dose
- **BIOLOGICAL:** MVA.HIVconsv high dose
- **OTHER:** Placebo high dose

## Key facts

- **NCT ID:** NCT01024842
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-12
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Slow recruitment therefore study was stopped after 95% volunteers were enrolled.
- **Last updated:** 2016-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01024842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01024842, "Safety and Immunogenicity of MVA.HIVconsv in HIV-1 Seropositive Adults on HAART". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01024842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*